EUR/USD 1.15364
0.037%
Gold 4337.56
0.181%
Oil 89.242
-0.549%
USD/JPY 160.181
0.007%
GBP/USD 1.33460
0.055%
GBP/JPY 213.781
0.066%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
June 9th - According to the Financial Times, Apollo Global Management and Blackstone Group have finalized a $35 billion private credit deal to fund Anthropics growth plans. This deal, spearheaded by these two private equity giants, is one of the largest private credit financings to date, as Wall Street banks and investment firms continue to pour money into the artificial intelligence boom. The funds will help Anthropic purchase chips developed by Alphabet. This deal highlights investors enormous enthusiasm for AI and their willingness to invest heavily in supporting the data center infrastructure and computing power needed by companies like Anthropic, OpenAI, and Meta. Neither Apollo nor Blackstone has commented on the matter.On Tuesday, June 9, the Hang Seng Index opened down 105.13 points, or 0.43%, at 24,551.93; the Hang Seng Tech Index opened down 12.39 points, or 0.26%, at 4,743.52; the H-share Index opened down 27.8 points, or 0.33%, at 8,313.56; and the Red Chip Index opened down 21.48 points, or 0.5%, at 4,313.91.Hong Kong stocks opened lower, with the Hang Seng Index down 0.43% and the Hang Seng Tech Index down 0.26%. AI applications, innovative drugs, chips, leading tech companies, and new energy vehicle companies were among the top gainers. Contron (01912.HK) resumed trading with a surge of over 110%, after receiving a mandatory cash offer from Zhuangyan-Investment-International.Hang Seng Index futures opened down 0.23% at 24,507 points, a discount of 150 points.June 9th - Shanghais car trade-in subsidy program has been adjusted to an instant lottery system. On the night of June 8th, the Shanghai Municipal Commission of Commerce issued an announcement regarding the adjustment of the lottery method for the 2026 Shanghai car trade-in subsidy program. The announcement states that from June 9th to September 30th, 2026, eligible individual consumers can register for the instant lottery through the "Government Services - Car Trade-in Subsidy Application" portal on the "Shanghai Commerce" WeChat official account from 7:00 AM to 10:00 PM daily.

U.S. Restricts Use of J&J's COVID Vaccine Due to Risk of Blood Clots

Charlie Brooks

May 06, 2022 09:38

J2.png


The US Food and Drug Administration said on Thursday that it will restrict adult use of Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccination owing to the danger of a rare blood clotting condition, the latest setback for the injection that has been supplanted by competitors.


The J&J shot, which was cleared for adult use in the United States in February 2021, may be used in situations when permitted or approved COVID-19 vaccinations are unavailable or if an user is averse to receiving the other two doses, the Food and Drug Administration said.


J&J is one of three vaccinations that are now in use in the United States. The remaining two are from Moderna (NASDAQ:MRNA) and Pfizer, respectively (NYSE:PFE).


The vaccine manufacturer said that it has amended the COVID-19 vaccination information sheet for the United States to include a warning regarding the risk of thrombosis associated with thrombocytopenia syndrome (TTS), an uncommon but potentially fatal illness.


In high-income nations, use of the J&J shot has been limited, owing to reports of rare, possibly fatal blood clots, manufacturing difficulties, including an unintentional component mix-up by a contract manufacturer, and doubts about effectiveness.


The manufacturer revised its projection for COVID-19 vaccine sales last month, citing a supply glut.


TTS, which is characterized by blood clots and a low platelet count, has previously been documented in recipients of the J&J vaccination.


The FDA changed the information sheet for the J&J vaccine in January to reflect the risk of immune thrombocytopenia, after months of similar action by the European Union's medicines authority.


The FDA stated Thursday that after conducting a study into reported instances, the risk of TTS justified restricting the use of the single-dose injection.


In December, the US Centers for Disease Control and Prevention suggested that Americans take mRNA doses from Pfizer or Moderna rather than J&J's vaccination owing to the possibility of blood clotting.


According to the CDC, about 18.7 million Americans got a J&J COVID-19 injection, compared to 217.5 million who received the Moderna vaccination and 340.6 million who received the Pfizer shot.

Suggestion